Drugs / BMD003
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07485543 | Mar → Dec 2026 expected | cystic fibrosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06963008 | May 2025 → May 2026 overdue | cystic fibrosis | Peking Union Medical College Hospital | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BMD003 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07485543 ↗ |
| Modality | Messenger RNA (mRNA) | “CFTR Mrna product” NCT06963008 ↗ |
| Route | Inhaled | “nebulized through a vibrating sieve atomizer, and inhaled into the lungs through the mouth and nose” NCT06963008 ↗ |
| Target | CFTR | “BMD003 is the world's first freeze-dried CFTR Mrna product” NCT06963008 ↗ |